$6.94
3.74% yesterday
Nasdaq, May 08, 10:17 pm CET
ISIN
US92337C1045
Symbol
VSTM
Sector
Industry

Verastem, Inc. Stock News

Neutral
Business Wire
about 9 hours ago
BOSTON--(BUSINESS WIRE)---- $VSTM #FDA--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Food and Drug Administration (FDA) has approved AVMAPKI™ FAKZYNJA™ CO-PACK (avutometinib capsules; defactinib tablets) for the treatment of adult patients with KRAS-mutated recu...
Positive
Reuters
about 10 hours ago
The U.S. Food and Drug Administration has approved Verastem's combination therapy for patients with a type of ovarian cancer who have received prior treatment, the regulator said on Thursday.
Neutral
Business Wire
8 days ago
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate and present at the following investor conferences in May: H.C. Wainwright 3rd Annual BioConnect Investor Conference: Fireside chat on Tuesday, May 20 at ...
Neutral
Business Wire
14 days ago
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors for a private placement of approximately $24 million of shares of its common stock at a price of ...
Neutral
Business Wire
15 days ago
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of VS-7375, an oral KRAS G12D (ON/OFF) inhibitor for clinical evaluation. The Company expects to initia...
Positive
Seeking Alpha
28 days ago
Verastem, Inc.'s priority review PDUFA date of avutometinib + defactinib for treatment of patients with recurrent LGSOC is expected June 30th of 2025; At this time, no FDA advisory committee to be held. The global Non-small cell lung cancer market size is projected to reach $36.9 billion by 2031; KRAS G12C variant is the most common KRAS mutation, accounting for 13% of NSCLC cases. Data from ph...
Neutral
Business Wire
about one month ago
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 164,500 shares of its common stock to fourteen new employees and the grant of 83,333 restricted stock units to one new employee. The awards were granted pursuant to the Nasdaq inducement grant...
Neutral
Business Wire
about one month ago
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, announced today multiple oral and poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025 to be held on April 25-30 in Chicago, Illinois. These presentations will highlight clinical ...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today